Tenderwize
Back to tender search

Medicines contracts with accession option

BARMER Beschaffung und Vergabe·Wuppertal, Germany·Deadline Nov 01, 2027 · 440 days left·Open·Supplies·Framework
Structured notice only
Original notice title

Germany – Pharmaceutical products – Arzneimittelverträge mit Beitrittsoption

30/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

30 / 100

Complexity

40 / 100

Risk factors

The notice explicitly states it is not a public procurement under EU directives. This may limit transparency, legal rec...

No estimated value or budget is provided. Bidders cannot assess the potential volume or revenue, making bid/no-bid deci...

No procurement documents available

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 3 lots
  • Duration until Dec 2027
  • Supply of pharmaceutical products under framework agreements with accession option (Beitrittsoption).
  • 7 lots covering active substances: Apremilast, Certolizumab pegol, Dolutegravir, Eltrombopag (excluding SAA), Eltrombopag (Revolade®), Guanfacin, Mesalazin.
Show full summary

This is a framework agreement with an accession option (Beitrittsoption) for the supply of pharmaceutical products, issued by BARMER Beschaffung und Vergabe (a German health insurance entity). The notice explicitly states that it is not a public procurement under Directive 2014/24/EU. There are 7 lots covering different active substances. The award is 100% based on price. No estimated value is provided. The deadline for submission is November 1, 2027, offering a very long submission period. The language of the procedure is German only. No procurement documents were analyzed beyond the notice, and key details such as eligibility criteria and required documents are missing.

Risks

The notice explicitly states it is not a public procurement under EU directives. This may limit transparency, legal rec...

No estimated value or budget is provided. Bidders cannot assess the potential volume or revenue, making bid/no-bid deci...

No procurement documents available

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • No variants allowed.

Administrative

  • Submission via electronic platform only: Open portal
  • Language of the procedure: German.

Requirements may be incomplete.

Award Criteria

Lot 1

Price criterion with weight 100 (per-exa).100%

Lot 2

Price criterion with weight 100 (per-exa).100%

Lot 3

Price criterion with weight 100 (per-exa).100%

Lot 4

Preis100%

Lot 5

Preis100%

Lot 6

Preis100%

Lot 7

Preis100%

Buyer

Location

Wuppertal, DEU

Identifier

992-80322-57

Activity

Health

Lots (7)

LOT-0001

Apremilast

Pharmaceutical products containing the active substance Apremilast.

SuppliesFrameworkEU fundedElectronic submission

Location

Wuppertal, Germany

Duration

Jan 2026 - Dec 2027

Category

Pharmaceutical products

Award Criteria

Price

Deadline

Deadline Nov 01, 2027

LOT-0002

Certolizumab pegol

Pharmaceutical products containing the active substance Certolizumab pegol.

SuppliesFrameworkEU fundedElectronic submission

Location

Wuppertal, Germany

Duration

Jan 2026 - Dec 2027

Category

Pharmaceutical products

Award Criteria

Price

Deadline

Deadline Nov 01, 2027

LOT-0003

Dolutegravir

Pharmaceutical products containing the active substance Dolutegravir.

SuppliesFrameworkEU fundedElectronic submission

Location

Wuppertal, Germany

Duration

Jan 2026 - Dec 2027

Category

Pharmaceutical products

Award Criteria

Price

Deadline

Deadline Nov 01, 2027

LOT-0004

Eltrombopag (ausgenommen SAA)

Vertragsgegenständlich sind Arzneimittel, die den/die im Titel genannte(n) Wirkstoff/Wirkstoffkombination enthalten.

SuppliesFrameworkEU fundedElectronic submission

Location

Wuppertal, Germany

Duration

Jan 2026 - Dec 2027

Category

Pharmaceutical products

Award Criteria

Preis

LOT-0005

Eltrombopag (Revolade®)

Vertragsgegenständlich sind Arzneimittel, die den/die im Titel genannte(n) Wirkstoff/Wirkstoffkombination enthalten.

SuppliesFrameworkEU fundedElectronic submission

Location

Wuppertal, Germany

Duration

Jan 2026 - Dec 2027

Category

Pharmaceutical products

Award Criteria

Preis

LOT-0006

Guanfacin

Vertragsgegenständlich sind Arzneimittel, die den/die im Titel genannte(n) Wirkstoff/Wirkstoffkombination enthalten.

SuppliesFrameworkEU fundedElectronic submission

Location

Wuppertal, Germany

Duration

Jan 2026 - Dec 2027

Category

Pharmaceutical products

Award Criteria

Preis

LOT-0007

Mesalazin (oral, ohne retard in 0,5 g, 1,0 g, 2,0 g, 4,0 g + TMR_500 mg)

Vertragsgegenständlich sind Arzneimittel, die den/die im Titel genannte(n) Wirkstoff/Wirkstoffkombination enthalten.

SuppliesFrameworkEU fundedElectronic submission

Location

Wuppertal, Germany

Duration

Jan 2026 - Dec 2027

Category

Pharmaceutical products

Award Criteria

Preis

Procurement Details

Publication date
18 Dec 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
848382-2025

Documents (1)

Similar tenders